Current Neuropharmacology
March 1, 2011
Yoko Hagino, Yukio Takamatsu, Hideko Yamamoto et al.
64 citations
MDMA increases extracellular dopamine and serotonin in the striatum and prefrontal cortex of mice. In mice lacking both dopamine and serotonin transporters, the dopamine increase in the striatum is absent, while the serotonin increase is greatly reduced. In the prefrontal cortex, MDMA raises dopamine levels regardless of transporter knockout. These findings confirm that MDMA acts on both the dopamine and serotonin transporters to elevate these neurotransmitters.
Current Neuropharmacology
March 1, 2011
Chiharu Sogawa, Norio Sogawa, Kazumi Ohyama et al.
50 citations
Methylone, a synthetic hallucinogenic amphetamine analog similar to MDMA, inhibits the activity of dopamine, norepinephrine, and serotonin transporters in a concentration-dependent manner, with the strongest effect on the norepinephrine transporter, followed by dopamine and then serotonin transporters. Compared to methamphetamine, methylone is less effective at blocking dopamine and norepinephrine transporters but more effective at blocking the serotonin transporter. Methylone alone is not toxic to cells except at high concentrations, but when combined with methamphetamine, it produces a synergistic toxic effect in cells that express monoamine transporters, likely because methylone acts as a transportable substrate that inhibits transporter function.
Neuropsychopharmacology Reports
February 6, 2021
Yoko Hagino, F. Scott Hall, George R. Uhl et al.
3 citations
The hallucinogenic tryptamine analogue 5-MeO-DIPT decreases extracellular serotonin in the striatum but not in the prefrontal cortex of mice. In mice lacking the serotonin transporter, 5-MeO-DIPT does not affect serotonin levels, indicating its action depends on that transporter. When a 5-HT1A receptor antagonist is present, 5-MeO-DIPT substantially increases serotonin, suggesting the drug's serotonin reuptake inhibition is masked by its concurrent activation of 5-HT1A receptors. 5-MeO-DIPT also dose-dependently increases extracellular dopamine in the prefrontal cortex regardless of serotonin transporter presence, an effect not blocked by the 5-HT1A antagonist. Thus, 5-MeO-DIPT dually acts on the serotonin transporter and 5-HT1A receptors, limiting serotonin elevation while independently raising dopamine in the prefrontal cortex.